What is MobileODT?
Founded in 2012, MobileODT specializes in the development of AI-driven colposcopy solutions designed to assist clinicians in the visual assessment of cervical health. By transforming standard mobile devices into sophisticated diagnostic tools, the company provides healthcare providers with real-time, data-backed insights that improve diagnostic accuracy and patient outcomes. MobileODT operates at the intersection of medical device innovation and software-as-a-service (SaaS) delivery, targeting a global market that is increasingly prioritizing point-of-care diagnostics and remote health monitoring. Their platform is engineered to reduce the barriers to entry for high-quality screening, particularly in resource-constrained environments, thereby democratizing access to essential women's health services.
How much funding has MobileODT raised?
MobileODT has raised a total of $10.8M across 2 funding rounds:
Series B
$6.8M
Series C
$4M
Series B (2017): $6.9M with participation from Tristel and OrbiMed Advisors LLC
Series C (2020): $4M led by Laerdal, Tristel, Tara Health, and OrbiMed Israel Partners
Key Investors in MobileODT
OrbiMed Advisors LLC
OrbiMed Advisors LLC is a premier healthcare-focused investment firm that manages capital across biopharmaceuticals, medical devices, and digital health platforms, providing deep operational expertise to its portfolio companies.
Tristel
Tristel is a global leader in infection prevention and contamination control, specializing in high-level disinfection solutions for medical devices, which aligns with the clinical focus of MobileODT.
Laerdal
Laerdal is a prominent organization dedicated to helping save lives through the development of innovative healthcare training and simulation products, often supporting ventures that improve clinical outcomes.
What's next for MobileODT?
With the recent influx of capital, MobileODT is well-positioned to accelerate its product development roadmap and expand its commercial reach. The strategic focus will likely center on deepening the integration of its AI algorithms into existing clinical workflows and pursuing regulatory milestones in key international markets. As the company transitions into its next phase of growth, the emphasis will remain on scaling its digital health infrastructure and fostering partnerships that enhance the clinical utility of its visual assessment tools. By maintaining a focus on evidence-based innovation, MobileODT is poised to solidify its leadership in the women's health technology sector, driving long-term value for both clinicians and patients alike.
See full MobileODT company page
